Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) announces that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world’s leading mid-market investors, in a transaction valued at up to $460 million, marking a significant step in Waldencast’s strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup. Founded in 1988, Obagi Medical (www.obagi.com) is a pioneer in medical-grade skincare. Rooted in advanced research and skin biology, the brand offers a distinctive portfolio of both prescription and non-prescription products.
Read the full article: Waldencast Announces Sale of Obagi Medical to Bridgepoint //
Source: https://www.globenewswire.com/news-release/2026/06/01/3304174/0/en/waldencast-announces-sale-of-obagi-medical-to-bridgepoint.html